Loomis Sayles & Co. L P Has $45.15 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Loomis Sayles & Co. L P increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 13.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,912,205 shares of the company's stock after buying an additional 458,601 shares during the period. Loomis Sayles & Co. L P owned 0.53% of Roivant Sciences worth $45,147,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ROIV. Mutual of America Capital Management LLC lifted its position in Roivant Sciences by 0.4% during the second quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company's stock valued at $3,457,000 after acquiring an additional 1,142 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Roivant Sciences by 23.2% during the 2nd quarter. Acadian Asset Management LLC now owns 8,510 shares of the company's stock valued at $89,000 after purchasing an additional 1,603 shares in the last quarter. Covestor Ltd raised its position in shares of Roivant Sciences by 9.1% in the third quarter. Covestor Ltd now owns 19,190 shares of the company's stock worth $222,000 after acquiring an additional 1,605 shares during the period. US Bancorp DE boosted its position in Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company's stock worth $38,000 after purchasing an additional 1,948 shares in the last quarter. Finally, Gladius Capital Management LP acquired a new stake in Roivant Sciences in the 3rd quarter valued at $35,000. Institutional investors own 64.76% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ROIV. Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 19th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, November 13th. Finally, Bank of America lifted their price objective on Roivant Sciences from $12.00 to $12.50 and gave the company a "neutral" rating in a research note on Wednesday, September 11th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $17.93.

Roivant Sciences Price Performance

ROIV stock traded up $0.24 on Tuesday, hitting $12.70. 5,508,276 shares of the company were exchanged, compared to its average volume of 5,864,448. Roivant Sciences Ltd. has a twelve month low of $8.61 and a twelve month high of $13.06. The business's fifty day moving average is $11.70 and its two-hundred day moving average is $11.34. The stock has a market capitalization of $9.24 billion, a price-to-earnings ratio of 2.21 and a beta of 1.24.

Insider Activity at Roivant Sciences

In other news, CAO Rakhi Kumar sold 250,000 shares of the company's stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $11.89, for a total value of $2,972,500.00. Following the completion of the sale, the chief accounting officer now directly owns 209,322 shares of the company's stock, valued at approximately $2,488,838.58. This represents a 54.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Matthew Gline sold 1,983,257 shares of the firm's stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the transaction, the chief executive officer now owns 17,870,543 shares of the company's stock, valued at approximately $210,693,701.97. This trade represents a 9.99 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 3,677,309 shares of company stock worth $43,283,184. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.